Lubris
Novartis takes on dry-eye market with drug in-licensing move
April 7, 2017Medical Communications, Sales and Marketing Lubris, Novartis, dry eye
Novartis has announced that its eyecare-focused division Alcon has in-licensed dry-eye drug ECF843 from US firm Lubris for ophthalmic indications …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
